DK1594498T3 - Anvendelse af etazolat til behandling af sygdomme - Google Patents

Anvendelse af etazolat til behandling af sygdomme

Info

Publication number
DK1594498T3
DK1594498T3 DK04712083T DK04712083T DK1594498T3 DK 1594498 T3 DK1594498 T3 DK 1594498T3 DK 04712083 T DK04712083 T DK 04712083T DK 04712083 T DK04712083 T DK 04712083T DK 1594498 T3 DK1594498 T3 DK 1594498T3
Authority
DK
Denmark
Prior art keywords
etazolate
diseases
treatment
Prior art date
Application number
DK04712083T
Other languages
English (en)
Inventor
Fabien Schweighoffer
Annelies Resink
Laurent Desire
Magali Rouquette
Original Assignee
Exonhit Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa filed Critical Exonhit Therapeutics Sa
Application granted granted Critical
Publication of DK1594498T3 publication Critical patent/DK1594498T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04712083T 2003-02-19 2004-02-18 Anvendelse af etazolat til behandling af sygdomme DK1594498T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0302021A FR2851247B1 (fr) 2003-02-19 2003-02-19 Methodes et compositions pour le traitement de pathologies degeneratives oculaires
PCT/FR2004/000366 WO2004073711A2 (fr) 2003-02-19 2004-02-18 Methodes impliquant la pde4, compositions et leur criblage pour le traitement de pathologies neurodegeneratives oculaires

Publications (1)

Publication Number Publication Date
DK1594498T3 true DK1594498T3 (da) 2009-11-16

Family

ID=32749687

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04712083T DK1594498T3 (da) 2003-02-19 2004-02-18 Anvendelse af etazolat til behandling af sygdomme

Country Status (13)

Country Link
US (1) US7872015B2 (da)
EP (1) EP1594498B1 (da)
JP (1) JP4620042B2 (da)
AU (2) AU2004212736B2 (da)
CA (1) CA2516266A1 (da)
DE (1) DE602004022137D1 (da)
DK (1) DK1594498T3 (da)
ES (1) ES2329039T3 (da)
FR (1) FR2851247B1 (da)
HK (1) HK1085645A1 (da)
IL (1) IL169821A0 (da)
PT (1) PT1594498E (da)
WO (1) WO2004073711A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275586A1 (en) * 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341264A4 (en) * 1987-01-23 1991-03-20 The General Hospital Corporation Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
US4904472A (en) * 1987-04-10 1990-02-27 The University Of Virginia Alumni Patent Foundation Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
JP3559282B2 (ja) * 1992-09-14 2004-08-25 ヴォルフ―ゲオルク フォルスマン ホスホジェステラーゼ ▲ｉｖ▼のインヒビターの新規使用
EP0758233B1 (en) 1994-04-21 2003-12-03 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
JPH08198876A (ja) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6228869B1 (en) * 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6329566B1 (en) * 1997-05-29 2001-12-11 The General Hospital Corporation Methods for the detection, treatment, and prevention of neurodegeneration
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
EP1175487A2 (en) * 1999-02-10 2002-01-30 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
EP1267903A4 (en) * 2000-02-08 2003-08-06 Pharmacia Corp METHODS OF TREATING GLAUCOMA
ES2236217T3 (es) * 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
JP2003534385A (ja) * 2000-06-01 2003-11-18 チルドレンズ メディカル センター コーポレーション 被験者の神経に有益な効果をもたらす方法および組成物
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
BR0207302A (pt) * 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
US6794387B2 (en) * 2001-03-28 2004-09-21 Pfizer Inc. Pharmaceutically active compounds
US7115623B2 (en) * 2001-06-12 2006-10-03 Aska Pharmaceuticals Co., Ltd. PDE IV inhibitors
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
SI1511516T1 (sl) 2002-05-28 2009-06-30 Nycomed Gmbh Topično uporaben farmacevtski pripravek
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
KR20050043923A (ko) * 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도

Also Published As

Publication number Publication date
JP4620042B2 (ja) 2011-01-26
US20060241062A1 (en) 2006-10-26
AU2004212736A1 (en) 2004-09-02
IL169821A0 (en) 2007-07-04
AU2009203081A1 (en) 2009-08-20
HK1085645A1 (en) 2006-09-01
WO2004073711A2 (fr) 2004-09-02
US7872015B2 (en) 2011-01-18
FR2851247A1 (fr) 2004-08-20
JP2006520753A (ja) 2006-09-14
AU2004212736B2 (en) 2009-04-30
WO2004073711A3 (fr) 2005-04-14
EP1594498A2 (fr) 2005-11-16
ES2329039T3 (es) 2009-11-20
DE602004022137D1 (de) 2009-09-03
EP1594498B1 (fr) 2009-07-22
CA2516266A1 (fr) 2004-09-02
PT1594498E (pt) 2009-09-28
FR2851247B1 (fr) 2007-06-29

Similar Documents

Publication Publication Date Title
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1556342T3 (da) Phenethanolaminderivat til behandling af respiratoriske sygdomme
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602006016150D1 (de) Vorbeugung von krankheiten bei kaiserschnitt-babies
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DE602004018587D1 (de) Staubschützende Wegwerfmaske
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK1962869T3 (da) Behandling af luftvejssygdomme